Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos Gonzalez

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
Leukemia & Lymphoma|June 27, 2009
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamideJoaquin Martínez-López, Ana Rivero, Inmaculada Rapado, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 21, 2024
Using Separate Single-Outcome Risk Presentations Instead of Integrated Multioutcome Formats Improves Comprehension in Discrete Choice ExperimentsMatthew J Wallace, E Hope Weissler, Jui-Chen Yang, et al.
Journal of Shoulder and Elbow Surgery|July 30, 2020
Surgical treatment for recurrent shoulder instability: factors influencing surgeon decision makingBrian C Lau, Carolyn A Hutyra, Juan Marcos Gonzalez, et al.
Vascular Medicine (London, England)|October 17, 2024
Quantifying patients' preferences on tradeoffs between mortality risk and reduced need for target vessel revascularization for claudicationShelby D Reed, Jessie Sutphin, Matthew J Wallace, et al.
Blood|April 29, 2009
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemiaCarlos M Santamaría, María C Chillón, Ramón García-Sanz, et al.
Leukemia Research|May 22, 2009
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogeneticsCarlos M Santamaría, Maria C Chillón, Ramón García-Sanz, et al.
The Lancet. Oncology|March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trialArnon P Kater, Önder Arslan, Fatih Demirkan, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Blood|September 23, 2010
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupMartin S Tallman, Haesook T Kim, Pau Montesinos, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaFranck Morschhauser, John Radford, Achiel Van Hoof, et al.
Leukemia & Lymphoma|June 27, 2009
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamideJoaquin Martínez-López, Ana Rivero, Inmaculada Rapado, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 21, 2024
Using Separate Single-Outcome Risk Presentations Instead of Integrated Multioutcome Formats Improves Comprehension in Discrete Choice ExperimentsMatthew J Wallace, E Hope Weissler, Jui-Chen Yang, et al.
Journal of Shoulder and Elbow Surgery|July 30, 2020
Surgical treatment for recurrent shoulder instability: factors influencing surgeon decision makingBrian C Lau, Carolyn A Hutyra, Juan Marcos Gonzalez, et al.
Vascular Medicine (London, England)|October 17, 2024
Quantifying patients' preferences on tradeoffs between mortality risk and reduced need for target vessel revascularization for claudicationShelby D Reed, Jessie Sutphin, Matthew J Wallace, et al.
Blood|April 29, 2009
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemiaCarlos M Santamaría, María C Chillón, Ramón García-Sanz, et al.
Leukemia Research|May 22, 2009
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogeneticsCarlos M Santamaría, Maria C Chillón, Ramón García-Sanz, et al.
The Lancet. Oncology|March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trialArnon P Kater, Önder Arslan, Fatih Demirkan, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Blood|September 23, 2010
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupMartin S Tallman, Haesook T Kim, Pau Montesinos, et al.
Pageof 18